CY1110092T1 - ΠΑΡΑΣΚΕΥΗ TNFR-Fc - Google Patents
ΠΑΡΑΣΚΕΥΗ TNFR-FcInfo
- Publication number
- CY1110092T1 CY1110092T1 CY20101100556T CY101100556T CY1110092T1 CY 1110092 T1 CY1110092 T1 CY 1110092T1 CY 20101100556 T CY20101100556 T CY 20101100556T CY 101100556 T CY101100556 T CY 101100556T CY 1110092 T1 CY1110092 T1 CY 1110092T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cumulative
- culture
- amino acid
- glutamine
- lactate
- Prior art date
Links
- 230000001186 cumulative effect Effects 0.000 abstract 10
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 229910001410 inorganic ion Inorganic materials 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχεται βελτιωμένο σύστημα για παραγωγή μεγάλης κλίμακας του TNFR-Fc σε κυτταροκαλλιέργεια, ιδιαιτέρως σε μέσο που χαρακτηρίζεται από ένα ή περισσότερα από: i) αθροιστική συγκέντρωση αμινοξέος μεγαλύτερη από 70 mM, ii) γραμμομοριακή αθροιστική αναλογία αθροιστικής γλουταμίνης προς αθροιστική ασπαραγίνη μικρότερη από περίπου 2, iii) γραμμομοριακή αναλογία αθροιστικής γλουταμίνης προς αθροιστικό ολικό αμινοξύ μικρότερη από περίπου 0,2, iv) γραμμομοριακή αναλογία αθροιστικού ανόργανου ιόντος προς αθροιστικό ολικό αμινοξύ μεταξύ περίπου 0,4 έως 1 ή v) συνδυασμένη συγκέντρωση αθροιστικής γλουταμίνης και αθροιστικής ασπαραγίνης μεταξύ περίπου 16 και 36 mM. Η χρήση ενός τέτοιου συστήματος επιτρέπει υψηλά επίπεδα παραγωγής πρωτεΐνης και μειώνει την συσσώρευση ορισμένων ανεπιθύμητων παραγόντων, όπως αμμωνίου ή/και γαλακτικού. Επιπροσθέτως, παρέχονται μέθοδοι καλλιέργειας που συμπεριλαμβάνουν μετατόπιση θερμοκρασίας που τυπικώς περιλαμβάνει μία μείωση στην θερμοκρασία όταν η καλλιέργεια έχει φτάσει περίπου 20-80% της μεγίστης πυκνότητας κυττάρου αυτής. Εναλλακτικά ή επιπροσθέτως, η παρούσα μέθοδος παρέχει μεθόδους, έτσι ώστε μετά την επίτευξη μιας κορύφωσης, τα επίπεδα γαλακτικού ή/και αμμωνίου στην καλλιέργεια μειώνονται συναρτήσει του χρόνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60537904P | 2004-08-27 | 2004-08-27 | |
EP08005732A EP1992697B1 (en) | 2004-08-27 | 2005-08-26 | Production of TNFR-Fc |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110092T1 true CY1110092T1 (el) | 2015-01-14 |
Family
ID=35500648
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100022T CY1109721T1 (el) | 2004-08-27 | 2010-01-08 | Παρασκευη πρωτεινης συντηξης tnfr-lg |
CY20101100556T CY1110092T1 (el) | 2004-08-27 | 2010-06-16 | ΠΑΡΑΣΚΕΥΗ TNFR-Fc |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100022T CY1109721T1 (el) | 2004-08-27 | 2010-01-08 | Παρασκευη πρωτεινης συντηξης tnfr-lg |
Country Status (38)
Country | Link |
---|---|
US (1) | US7300773B2 (el) |
EP (2) | EP1781802B1 (el) |
JP (3) | JP2008511330A (el) |
KR (1) | KR100988451B1 (el) |
CN (2) | CN101061231B (el) |
AR (2) | AR050537A1 (el) |
AT (2) | ATE461285T1 (el) |
AU (1) | AU2005280036B2 (el) |
BR (1) | BRPI0514694B8 (el) |
CA (1) | CA2578138C (el) |
CL (1) | CL2017000577A1 (el) |
CR (2) | CR8998A (el) |
CY (2) | CY1109721T1 (el) |
DE (2) | DE602005017285D1 (el) |
DK (2) | DK1781802T3 (el) |
EC (1) | ECSP077354A (el) |
EG (1) | EG26922A (el) |
ES (2) | ES2335518T3 (el) |
GT (2) | GT200500234A (el) |
HK (2) | HK1121497A1 (el) |
HN (1) | HN2005000485A (el) |
HR (2) | HRP20100011T1 (el) |
IL (1) | IL181588A (el) |
MX (1) | MX2007002381A (el) |
MY (1) | MY137803A (el) |
NO (1) | NO344785B1 (el) |
NZ (1) | NZ579208A (el) |
PE (2) | PE20100448A1 (el) |
PL (2) | PL1781802T3 (el) |
PT (2) | PT1781802E (el) |
RS (2) | RS51255B (el) |
RU (1) | RU2458988C2 (el) |
SI (2) | SI1781802T1 (el) |
SV (1) | SV2006002211A (el) |
TW (1) | TWI364458B (el) |
UA (1) | UA89383C2 (el) |
WO (1) | WO2006026447A2 (el) |
ZA (1) | ZA200701672B (el) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
SG162788A1 (en) | 2005-06-14 | 2010-07-29 | Amgen Inc | Self-buffering protein formulations |
AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
KR101495549B1 (ko) * | 2006-07-13 | 2015-02-25 | 와이어쓰 엘엘씨 | 당단백질의 생산 |
CA2666317C (en) * | 2006-11-03 | 2013-08-06 | Wyeth | Glycolysis-inhibiting substances in cell culture |
TW200827445A (en) * | 2006-11-08 | 2008-07-01 | Wyeth Corp | Rationally designed media for cell culture |
JP5586235B2 (ja) | 2007-03-02 | 2014-09-10 | ワイス・エルエルシー | ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用 |
TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
US20110137012A1 (en) | 2007-04-26 | 2011-06-09 | Chugai Seiyaku Kabushiki Kaisha | Cell culture method using amino acid-enriched medium |
KR101286895B1 (ko) * | 2008-04-17 | 2013-07-16 | 와이어쓰 엘엘씨 | 골 형태발생 단백질의 개선된 생산 방법 |
US20110111495A1 (en) * | 2008-04-18 | 2011-05-12 | Shanghai Cp Guojian Pharmaceutical Co. Ltd | Concentrated medium and its usage |
EP2331700A2 (en) | 2008-08-08 | 2011-06-15 | Biogen Idec MA Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
SG10201901417UA (en) | 2009-08-11 | 2019-03-28 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
CN102770458A (zh) * | 2009-12-02 | 2012-11-07 | 阿塞勒隆制药公司 | 用于增加Fc融合蛋白的血清半寿期的组合物和方法 |
CA2795461C (en) | 2010-04-26 | 2018-04-24 | Novartis Ag | Improved cell cultivation process |
CN102858953B (zh) | 2010-04-26 | 2015-09-09 | 诺瓦提斯公司 | 改进的细胞培养基 |
CA2807607A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
EP2640483A1 (en) * | 2010-11-15 | 2013-09-25 | Biogen Idec Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
PL2702164T3 (pl) | 2011-04-29 | 2016-06-30 | Biocon Res Limited | Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania |
US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
PT2768525T (pt) | 2011-10-18 | 2019-07-17 | Coherus Biosciences Inc | Formulações etanercept estabilizadas com iões de magnésio |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
EP2768944B2 (en) * | 2011-10-21 | 2023-11-22 | Pfizer Inc. | Addition of iron to improve cell culture |
CN104159916A (zh) * | 2012-02-22 | 2014-11-19 | Nvip私人有限公司 | 肿瘤坏死因子受体融合蛋白及其使用方法 |
EP2869817A4 (en) | 2012-07-09 | 2016-04-06 | Coherus Biosciences Inc | STABLE AQUEOUS FORMULATIONS OF ETANERCEPT |
PL2895188T3 (pl) | 2012-09-11 | 2018-06-29 | Coherus Biosciences, Inc. | Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
JP6689189B2 (ja) | 2013-03-26 | 2020-04-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | タンパク質産生方法 |
KR101439195B1 (ko) | 2013-04-18 | 2014-09-12 | 동아대학교 산학협력단 | 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정 |
KR102243980B1 (ko) * | 2013-10-11 | 2021-04-26 | 리제너론 파마슈티칼스 인코포레이티드 | 대사적으로 최적화된 세포 배양 |
US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
EP3683316A1 (en) * | 2014-01-30 | 2020-07-22 | Coherus Biosciences, Inc. | Perfusion media |
KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
ES2784503T3 (es) * | 2014-12-01 | 2020-09-28 | Amgen Inc | Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína |
KR102007930B1 (ko) | 2014-12-31 | 2019-08-06 | 주식회사 엘지화학 | 재조합 당단백질의 글리코실화 조절 방법 |
CN105777897A (zh) * | 2015-03-20 | 2016-07-20 | 广东东阳光药业有限公司 | 一种cho细胞收获液的前处理方法 |
CA3208857A1 (en) * | 2015-04-01 | 2016-10-06 | Boehringer Ingelheim International Gmbh | Cell culture medium |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
MX2019004580A (es) | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
CN110484487A (zh) * | 2019-08-21 | 2019-11-22 | 安徽欣乐生物技术有限公司 | 一种适用于cho细胞培养用无蛋白培养基及其培养方法 |
MX2023006998A (es) | 2020-12-22 | 2023-06-26 | Amgen Inc | Metodo de cultivo celular. |
CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
CN114480492B (zh) * | 2022-01-28 | 2023-04-21 | 景泽生物医药(合肥)股份有限公司 | 一种重组人抗体融合蛋白的制备方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU632065B2 (en) * | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
US5156964A (en) | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
GB9118664D0 (en) | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片 |
US6310185B1 (en) | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5589154A (en) | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US20020012991A1 (en) * | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
ES2318006T3 (es) | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
EP1385544B1 (en) | 2001-04-30 | 2008-09-24 | Eli Lilly And Company | Humanized antibodies |
EP1404813A4 (en) | 2001-06-13 | 2004-11-24 | Genentech Inc | METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
CA2476887A1 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Gasp1:a follistatin domain containing protein |
PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1507556B1 (en) | 2002-05-02 | 2016-07-27 | Wyeth Holdings LLC | Calicheamicin derivative-carrier conjugates |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
-
2005
- 2005-08-25 US US11/213,633 patent/US7300773B2/en active Active
- 2005-08-25 TW TW094129077A patent/TWI364458B/zh not_active IP Right Cessation
- 2005-08-26 SI SI200530874T patent/SI1781802T1/sl unknown
- 2005-08-26 GT GT200500234A patent/GT200500234A/es unknown
- 2005-08-26 AR ARP050103596A patent/AR050537A1/es not_active Application Discontinuation
- 2005-08-26 RS RSP-2010/0190A patent/RS51255B/sr unknown
- 2005-08-26 DK DK05791482.2T patent/DK1781802T3/da active
- 2005-08-26 UA UAA200703287A patent/UA89383C2/ru unknown
- 2005-08-26 MY MYPI20054023A patent/MY137803A/en unknown
- 2005-08-26 NZ NZ579208A patent/NZ579208A/en not_active IP Right Cessation
- 2005-08-26 SI SI200530984T patent/SI1992697T1/sl unknown
- 2005-08-26 EP EP05791482A patent/EP1781802B1/en not_active Revoked
- 2005-08-26 GT GT200500233A patent/GT200500233A/es unknown
- 2005-08-26 AT AT08005732T patent/ATE461285T1/de active
- 2005-08-26 AT AT05791482T patent/ATE446376T1/de active
- 2005-08-26 RU RU2007108717/10A patent/RU2458988C2/ru active
- 2005-08-26 EP EP08005732A patent/EP1992697B1/en not_active Revoked
- 2005-08-26 PE PE2009001227A patent/PE20100448A1/es active IP Right Grant
- 2005-08-26 PT PT05791482T patent/PT1781802E/pt unknown
- 2005-08-26 ES ES05791482T patent/ES2335518T3/es active Active
- 2005-08-26 DK DK08005732.6T patent/DK1992697T3/da active
- 2005-08-26 CN CN2005800369388A patent/CN101061231B/zh not_active Expired - Fee Related
- 2005-08-26 DE DE602005017285T patent/DE602005017285D1/de active Active
- 2005-08-26 PE PE2005000987A patent/PE20060815A1/es not_active Application Discontinuation
- 2005-08-26 PT PT08005732T patent/PT1992697E/pt unknown
- 2005-08-26 AU AU2005280036A patent/AU2005280036B2/en active Active
- 2005-08-26 MX MX2007002381A patent/MX2007002381A/es active IP Right Grant
- 2005-08-26 HN HN2005000485A patent/HN2005000485A/es unknown
- 2005-08-26 BR BRPI0514694A patent/BRPI0514694B8/pt active IP Right Grant
- 2005-08-26 CA CA2578138A patent/CA2578138C/en active Active
- 2005-08-26 RS RSP-2009/0575A patent/RS51072B/sr unknown
- 2005-08-26 DE DE602005020076T patent/DE602005020076D1/de active Active
- 2005-08-26 WO PCT/US2005/030439 patent/WO2006026447A2/en active Application Filing
- 2005-08-26 PL PL05791482T patent/PL1781802T3/pl unknown
- 2005-08-26 KR KR1020077004810A patent/KR100988451B1/ko active IP Right Grant
- 2005-08-26 CN CN2012102771283A patent/CN102876761A/zh active Pending
- 2005-08-26 PL PL08005732T patent/PL1992697T3/pl unknown
- 2005-08-26 SV SV2005002211A patent/SV2006002211A/es unknown
- 2005-08-26 JP JP2007530167A patent/JP2008511330A/ja active Pending
- 2005-08-26 ES ES08005732T patent/ES2341390T3/es active Active
-
2007
- 2007-02-26 ZA ZA2007/01672A patent/ZA200701672B/en unknown
- 2007-02-27 IL IL181588A patent/IL181588A/en unknown
- 2007-02-27 EG EGNA2007000222 patent/EG26922A/xx active
- 2007-03-16 CR CR8998A patent/CR8998A/es unknown
- 2007-03-26 NO NO20071570A patent/NO344785B1/no not_active IP Right Cessation
- 2007-03-27 EC EC2007007354A patent/ECSP077354A/es unknown
- 2007-07-16 HK HK09102060.2A patent/HK1121497A1/xx not_active IP Right Cessation
- 2007-07-16 HK HK07107585.9A patent/HK1099941A1/xx not_active IP Right Cessation
-
2010
- 2010-01-08 CY CY20101100022T patent/CY1109721T1/el unknown
- 2010-01-11 HR HR20100011T patent/HRP20100011T1/hr unknown
- 2010-05-14 HR HR20100271T patent/HRP20100271T1/hr unknown
- 2010-06-16 CY CY20101100556T patent/CY1110092T1/el unknown
-
2012
- 2012-02-17 JP JP2012033112A patent/JP5921910B2/ja active Active
- 2012-11-01 CR CR20120560A patent/CR20120560A/es unknown
- 2012-11-09 AR ARP120104234A patent/AR088824A2/es not_active Application Discontinuation
-
2016
- 2016-01-28 JP JP2016014650A patent/JP2016056214A/ja active Pending
-
2017
- 2017-03-09 CL CL2017000577A patent/CL2017000577A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110092T1 (el) | ΠΑΡΑΣΚΕΥΗ TNFR-Fc | |
MX2007002382A (es) | Producci??n de anticuerpos anti-amiloides beta. | |
SG158092A1 (en) | Production of polypeptides | |
EA202090067A2 (ru) | Способ получения рекомбинантного adamts13 в культуре клеток | |
EA200801439A1 (ru) | Способы производства частиц оксида титана, частицы и вещества, полученные этими способами | |
ATE501252T1 (de) | Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns | |
PE20020887A1 (es) | Metodo para producir acido l-glutamico | |
ATE478063T1 (de) | Verfahren zur herstellung von alkylencarbonat | |
ATE428730T1 (de) | Verfahren zur herstellung einer alpha-1- antitrypsinlösung | |
RU2008122946A (ru) | Композиция для выпрямления волос, включающая дисахарид | |
TR199802146T2 (xx) | Saf azetidin-2-karboksilik asitin �retilmesi i�in geli�tirilmi� y�ntem | |
RU2009117253A (ru) | Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании | |
ATE423841T1 (de) | Verwendung von glutaminfreien medium | |
NO20033707L (no) | Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr | |
NO20033706L (no) | Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr | |
BR0214646A (pt) | Processo para tratar um meio aquoso contendo sal de fosfato e compostos orgânicos | |
EA200500763A1 (ru) | Композиции ифосфамида для парентерального введения и способ их получения | |
PT1246824E (pt) | Derivados de diazepina-carboxamida, processo para a sua preparacao, sua aplicacao como medicamentos, composicoes farmaceuticas e sua utilizacao |